Urgent Updates | February 2, 2022

TREATMENT OF MULTIDRUG-RESISTANT GRAM-NEGATIVE BACILLI CLINICAL PRACTICE GUIDELINES (ESCMID, 2021) Guidelines for the treatment of multidrug-resistant gram-negative bacilli were published in December 2021 by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) with the endorsement of the European Society of Intensive Care Medicine (ESICM). For bloodstream infection (BSI) and severe infection due to

Urgent Updates | January 26, 2022

CDC UPDATES CONSUMER MASK WEBSITE TO EMPHASIZE PROTECTION, FIT, AND COMFORT Masking is a critical public health tool to prevent the spread of COVID-19, and it is important to remember that any mask is better than no mask. CDC continues to recommend wearing the most protective mask that fits well and will wear consistently. Clarified

Urgent Updates | January 19, 2022

Urgent Updates – January 19, 2022 EFFECT OF SUBCUTANEOUS CASIRIVIMAB AND IMDEVIMAB ANTIBODY COMBINATION VS PLACEBO ON DEVELOPMENT OF SYMPTOMATIC COVID-19 IN EARLY ASYMPTOMATIC SARS-COV-2 INFECTION. A RANDOMIZED CLINICAL TRIAL In this randomized clinical trial that included 314 SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living with an infected household contact, 29.0% of asymptomatic seronegative participants

Urgent Updates | January 5, 2022

Urgent Updates – January 5, 2022 OMICRON DOES NOT EVADE T CELLSOmicron’s mutations help it escape from antibodies, but T cells are highly effective at recognizing and attacking the Omicron variant. Despite Omicron’s extensive mutations and reduced susceptibility to neutralizing antibodies, the majority of T cell response, induced by vaccination or natural infection, cross-recognizes the variant.Full

Urgent Updates | December 30, 2021

Urgent Updates – December 30, 2021 RISANKIZUMAB IN SEVERE ASTHMA — A PHASE 2A, PLACEBO-CONTROLLED TRIALPLACEBO BEAT RISANKIZUMAB IN ADULTS WITH SEVERE ASTHMAThe randomized, double-blind, 24-week, parallel group, multicenter trial assessed risankizumab efficacy and safety in 214 adults with severe persistent asthma. Placebo treatment was found to be superior to treatment with risankizumab with respect to

Urgent Updates | December 24, 2021

Urgent Updates – December 24, 2021 COMPARED TO POLIO AND SMALLPOX, AMERICA’S COVID-19 VACCINATION CAMPAIGN IS GOING GREATVaccine hesitancy is undeniably an obstacle in the fight against COVID-19. Sometimes, dramatically reducing the incidence of a disease requires only adequate, not absolute, compliance with a public-health regimen. In addition, the more insistently a vaccination campaign is pursued,

Urgent Updates | December 10, 2021

Urgent Updates – December 10, 2021 EVALUATION OF PHARMACOLOGIC TREATMENTS FOR H1 ANTIHISTAMINE–REFRACTORY CHRONIC SPONTANEOUS URTICARIAA SYSTEMATIC REVIEW AND NETWORK META-ANALYSISIn this network meta-analysis of 23 randomized clinical trials including 2480 participants, the biologic agents ligelizumab, 72 or 240 mg (large beneficial effect), and omalizumab, 300 or 600 mg (moderate beneficial effect), appeared to be effective

Urgent Updates | December 3, 2021

Urgent Updates – December 3, 2021 NEW COVID VARIANT OF CONCERN DRIVES US TRAVEL BANSThe World Health Organization (WHO) on Friday classified a new COVID-19 variant (B.1.1.529/Omicron) from South Africa as a variant of concern, which means it could be more contagious, cause more severe disease, and reduce the efficacy of vaccines and treatments. his variant has

Urgent Updates | November 26, 2021

Urgent Updates – November 26, 2021 ASSOCIATIONS BETWEEN AMBIENT FINE PARTICULATE MATTER AND CHILD RESPIRATORY INFECTION: THE ROLE OF PARTICULATE MATTER SOURCE COMPOSITION IN DHAKA, BANGLADESH.Short-term increases in ambient air pollution were associated with a rise in the incidence of pneumonia in children, according to a large, community-based study in Bangladesh.Of 28,089 clinic visits included

Urgent Updates | November 19, 2021

ASPERGILLOSIS IS COMMON AMONG COVID-19 PATIENTS IN THE ICU A multinational study published in the CDC journal Emerging Infectious Diseases shows that as many as 15% of patients with COVID-19 who are hospitalized in an intensive care unit (ICU) develop Aspergillus infection. Damage to the lining of airways from severe SARS-CoV-2 infection allows Aspergillus fungi to invade the tissue. These secondary